Key Points
- Insider Jordan Clark sold 250,000 Diaceutics shares at an average price of GBX 190, for proceeds of £475,000.
- Diaceutics shares were down 0.5% in the report, with a 12-month trading range of GBX 125 to GBX 210.
- Analyst sentiment remained positive: two analysts rated the stock a Buy, with an average price target of GBX 215.
Diaceutics PLC (LON:DXRX - Get Free Report) insider Jordan Clark sold 250,000 shares of Diaceutics stock in a transaction on Thursday, November 12th. The stock was sold at an average price of GBX 190, for a total value of £475,000.
Diaceutics Trading Down 0.5%
LON DXRX opened at GBX 194 on Friday. The stock has a 50-day simple moving average of GBX 189.12 and a 200 day simple moving average of GBX 160.98. The company has a market capitalization of £164.85 million, a PE ratio of -606.25 and a beta of 0.88. The company has a current ratio of 2.55, a quick ratio of 9.92 and a debt-to-equity ratio of 5.40. Diaceutics PLC has a 12 month low of GBX 125 and a 12 month high of GBX 210.
Diaceutics (LON:DXRX - Get Free Report) last issued its earnings results on Tuesday, September 22nd. The company reported GBX (3.27) earnings per share (EPS) for the quarter. Diaceutics had a negative return on equity of 0.68% and a negative net margin of 0.66%. Research analysts forecast that Diaceutics PLC will post 1.01 EPS for the current year.
Analyst Upgrades and Downgrades
Separately, Canaccord Genuity Group reiterated a "buy" rating and issued a GBX 215 price target on shares of Diaceutics in a research report on Tuesday. Two equities research analysts have rated the stock with a Buy rating. According to MarketBeat, Diaceutics presently has an average rating of "Buy" and an average price target of GBX 215.
View Our Latest Stock Analysis on Diaceutics
About Diaceutics
(
Get Free Report)
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
